We review goodwill for impairment during the fourth quarter of each fiscal year or more frequently if events or circumstances indicate that an impairment loss may have occurred. In the fourth quarter of fiscal 2025, we completed the annual impairment test of goodwill, which indicated there was no goodwill impairment. There were no indicators of goodwill impairment during the three months ended September 27, 2025.

Our intangible assets are amortized on a straight-line basis over the estimated useful lives, except for certain customer relationships, which are amortized using an accelerated method of amortization over the expected customer lives, more accurately reflecting the pattern of realization of economic benefits we expect to derive. Acquired developed technologies are amortized to cost of sales and research and development expenses. Acquired customer relationships are amortized to selling, general and administrative expenses in the consolidated statement of operations.

In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When an IPR&D project is completed, the IPR&D is reclassified to an amortizable purchased intangible asset and amortized over the asset’s estimated useful life.

During the annual impairment testing performed in the fourth quarter of fiscal 2025, we concluded that our intangible and other long-lived assets were not impaired at the asset group level. We review our intangible and other long-lived assets for impairment at least annually in the fourth quarter of each fiscal year, absent any interim indicators of impairment. There were no indicators of impairment at the asset group level during the three months ended September 27, 2025.

The following tables present details of all of our intangible assets as of the periods presented (in millions, except for weighted average remaining amortization period):


September 27, 2025	Gross Carrying Amounts		Accumulated Amortization		Net Carrying Amounts		Weighted Average Remaining Amortization Period (Years)
Acquired developed technologies	$	826.4	$	(579.3)	$	247.1	3.9
Customer relationships	419.5		(240.4)		179.1		3.9
In-process research and development	4.5		—		4.5		n/a
Order backlog	14.0		(14.0)		—		—
Trade name and trademarks	3.0		(3.0)		—		—
Total intangible assets	$	1,267.4	$	(836.7)	$	430.7


June 28, 2025	Gross Carrying Amounts		Accumulated Amortization		Net Carrying Amounts		Weighted Average Remaining Amortization Period (Years)
Acquired developed technologies	$	822.4	$	(559.0)	$	263.4	4.1
Customer relationships	419.8		(226.6)		193.2		4.1
In-process research and development	8.5		—		8.5		n/a
Order backlog	14.0		(14.0)		—		—
Trade name and trademarks	3.0		(3.0)		—		—
Total intangible assets	$	1,267.7	$	(802.6)	$	465.1


	Three Months Ended
	September 27, 2025		September 28, 2024
Cost of sales	$	19.5	$	22.5
Research and development	0.4		0.4
Selling, general and administrative	14.5		18.8
Total amortization of intangibles	$	34.4	$	41.7

Based on the carrying amount of our acquired intangible assets except in-process research and development as of September 27, 2025, and assuming no future impairment of the underlying assets, the estimated future amortization is as follows (in millions):


Fiscal Years
Remainder of 2026	$	101.1
2027	123.1
2028	82.6
2029	52.3
2030	46.3
Thereafter	20.8
Total future amortization	$	426.2